Balaji Gandhi Sells 5,771 Shares of Phreesia, Inc. (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 5,771 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $30.04, for a total value of $173,360.84. Following the sale, the chief financial officer now owns 105,514 shares of the company’s stock, valued at $3,169,640.56. This trade represents a 5.19 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Balaji Gandhi also recently made the following trade(s):

• On Thursday, February 13th, Balaji Gandhi sold 28,759 shares of Phreesia stock. The stock was sold at an average price of $30.00, for a total transaction of $862,770.00.
• On Monday, January 27th, Balaji Gandhi sold 4,813 shares of Phreesia stock. The shares were sold at an average price of $27.48, for a total transaction of $132,261.24.
• On Tuesday, January 21st, Balaji Gandhi sold 5,827 shares of Phreesia stock. The stock was sold at an average price of $27.31, for a total transaction of $159,135.37.
• On Wednesday, January 15th, Balaji Gandhi sold 836 shares of Phreesia stock. The shares were sold at an average price of $26.98, for a total transaction of $22,555.28.
• On Monday, January 6th, Balaji Gandhi sold 3,195 shares of Phreesia stock. The stock was sold at an average price of $26.61, for a total value of $85,018.95.

Phreesia Stock Performance

Shares of NYSE PHR opened at $28.20 on Friday. The company has a 50 day simple moving average of $27.29 and a two-hundred day simple moving average of $23.84. The stock has a market cap of $1.64 billion, a price-to-earnings ratio of -19.18 and a beta of 0.96. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04. Phreesia, Inc. has a 12 month low of $17.07 and a 12 month high of $30.53.

Phreesia (NYSE:PHR) last posted its earnings results on Monday, December 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. The company had revenue of $106.80 million during the quarter, compared to the consensus estimate of $106.33 million. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The firm’s quarterly revenue was up 16.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.58) earnings per share. As a group, analysts predict that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Institutional Trading of Phreesia

A number of hedge funds have recently modified their holdings of PHR. PharVision Advisers LLC purchased a new position in Phreesia during the fourth quarter valued at approximately $302,000. Two Sigma Advisers LP acquired a new stake in shares of Phreesia during the 4th quarter worth approximately $302,000. Silvercrest Asset Management Group LLC increased its holdings in shares of Phreesia by 31.0% during the 4th quarter. Silvercrest Asset Management Group LLC now owns 394,352 shares of the company’s stock valued at $9,922,000 after purchasing an additional 93,349 shares in the last quarter. ProShare Advisors LLC lifted its stake in shares of Phreesia by 49.0% in the 4th quarter. ProShare Advisors LLC now owns 15,585 shares of the company’s stock valued at $392,000 after purchasing an additional 5,127 shares during the period. Finally, Nuveen Asset Management LLC boosted its holdings in Phreesia by 77.1% during the fourth quarter. Nuveen Asset Management LLC now owns 235,827 shares of the company’s stock worth $5,933,000 after buying an additional 102,662 shares in the last quarter. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Analyst Ratings Changes

PHR has been the subject of a number of recent analyst reports. KeyCorp raised their price objective on Phreesia from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 8th. Robert W. Baird lowered their price target on Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Royal Bank of Canada upgraded shares of Phreesia from a “sector perform” rating to an “outperform” rating and upped their price objective for the company from $24.00 to $32.00 in a report on Wednesday, January 8th. JMP Securities reiterated a “market outperform” rating and issued a $30.00 target price on shares of Phreesia in a research note on Tuesday, December 10th. Finally, Needham & Company LLC reissued a “buy” rating and set a $29.00 target price on shares of Phreesia in a research report on Friday, January 10th. Thirteen research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Phreesia has a consensus rating of “Buy” and a consensus target price of $31.15.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.